Tuesday, October 4, 2022


Biotechnology News Magazine

Robert Glassman MD Appointed to Jubilant Therapeutics Board of Directors

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Robert Glassman MD will serve as an independent, non-executive director, effective February 1, 2021.

“Rob’s experience and insights will bring new dimension to the company as we chalk our growth strategy and we warmly welcome him to our board,” said Hari Bhartia, Chairman, Jubilant Therapeutics.

“Rob is a recognized leader in the biopharma industry and his oncology background and financial acumen will be invaluable as we execute on our strategic goals,” said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics.

Robert Glassman MD is the venture partner in public equity for OrbiMed Advisors, with more than 17 years of experience in investment banking, most recently having served as Managing Director and Vice Chairman in the Global Investment Banking Group at Credit Suisse since 2015. Prior to Credit Suisse, Dr. Glassman was with Merrill Lynch Global Private Equity where he oversaw a very successful healthcare portfolio. Earlier, he consulted for a wide range of healthcare clients in the U.S. and Europe at McKinsey & Company. Formerly a board-certified hematologist-oncologist, he remains on the faculty of Weill Cornell as a Clinical Assistant Professor of Medicine.

Dr. Glassman received his AB magna cum laude from Harvard College and an MD from Harvard Medical School. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, and his fellowship in hematology and oncology at Weill Cornell. He was an investigator at Rockefeller University in the laboratory of Hidesaburo Hanafusa where he received Howard Hughes Medical Institute and American Cancer Society awards. He currently serves on the Boards of Taurus Therapeutics, Umoja Biopharma and Pharvaris.

“I am honored to join the board of Jubilant Therapeutics and contribute to the important work the company is doing in the areas of genetically-defined cancers and autoimmune disorders,” said Dr. Glassman. “Their portfolio of targeted therapeutics is truly differentiated and potentially transformative for patients”.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine